Barbara Klencke — Endo Lab

article 2023

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

·doi:10.1016/s0140-6736(22)02036-0

BackgroundJanus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK…

article 2023

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

·doi:10.1016/s2352-3026(23)00174-6

BackgroundThe MOMENTUM study met all key endpoints at week 24, demonstrating symptom, spleen, and anaemia benefits with momelotinib versus danazol in patients with myelofibrosis. In this updated analysis, we report duration of week 24 respo…

editorial 2022

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications

·doi:10.1097/hs9.0000000000000778

Anemia is a prevalent and burdensome clinical manifestation of myelofibrosis (MF) with a complex etiology. Most MF patients are anemic within 1 year of diagnosis, and nearly all become dependent on red blood cell transfusions over time.1 An…